SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves quarterly results beat expectations and the company raised its outlook, with a large revenue backlog and expected customer prepayments drawing attention. Bulls say strong AI-compute demand and contract-backed funding ease financing concerns, while bears remain focused on heavy debt, interest costs and capital spending; the share reaction has been muted despite the upbeat results.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlists Q3 results and earnings call are driving attention, with traders focused on Samsung licensing revenue, improving profitability and margins, and expected recurring Micron payments and stronger product sales ahead. Bullish reactions emphasize the stronger financial outlook, while skeptics point to lower quarter-over-quarter product sales and the lack of confirmed SK Hynix or Nasdaq updates; speculation about a Hynix deal remains unconfirmed.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors pending FDA decision on deramiocel for Duchenne muscular dystrophy dominates discussion, with traders parsing managements comments on labeling and launch readiness as possible signs of approval. Optimism about the drugs prospects and cardiac data is countered by concerns that approval is uncertain and the decision could bring a sharp downside; the earnings report and a dispute with NS Pharma are secondary topics.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigettis Q3 results missed expectations, prompting concern about weak revenue, ongoing losses, and a long path to commercialization. Bears question the valuation of a pre-revenue quantum-computing business, while bulls argue that technical progress and the sectors long-term potential matter more than current financials.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidias selloff is focused on the board investigation into CEO Jensen Huangs acknowledged affair with an executive alleged to have ties to Chinese intelligence, and speculation about possible disclosure or export-control risks; the claims of compromised company secrets remain unsubstantiated. Traders are divided between viewing the controversy and potential leadership risk as grounds for further downside and treating the decline as a buying opportunity because they believe Nvidias AI business remains strong.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costcos declared special cash dividend and renewed stock-buyback authorization are driving attention, with traders welcoming the large payout while noting the share price adjusts for the dividend on the ex-date. The reaction is broadly upbeat, though some remain focused on Costcos premium valuation and caution that the dividend is not free money.

LightPath Technologies, Inc. engages in the design, development, manufacture, and distribution of optical and infrared components. Its products include molded glass and assemblies, infrared molded lenses, diamond turned, conventional ground and polished ground lenses and assemblies, and collimator assemblies, which are used in applications involving light detection and ranging technology. The firm supports a range of customers in the field of industrial, laser, defense, medical, telecommunications, and instrumentation. The company was founded in1985 and is headquartered in Orlando, FL.

Lightpath Technologies, Inc. - Ordinary Shares - Class A

LightPaths quarterly results are driving attention: revenue came in below expectations, while earnings per share beat and the company reported a record backlog and improved gross margins. Traders are split between viewing backlog growth and supply-chain recovery as evidence of strong execution and worrying that delayed deliveries and the revenue miss undermine the growth story.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

RUM is drawing attention around its scheduled Q3 earnings report, with traders debating whether Quake AI and the Northern Data acquisition will deliver the expected revenue growth. Bulls point to AI infrastructure demand and high short interest, while skeptics focus on cash burn, financing and dilution risks, as well as uncertainty around the reported Anthropic agreement.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

Kuras Q3 results and call have focused attention on growing KOMZIFTI use, with traders highlighting higher prescriptions and patient starts and praising managements defense of the drugs position against J&J competition. The reaction is broadly encouraged by the launch momentum, though some traders are concerned about a stock issuance and debate how competitive J&Js data may prove.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius quarterly report is driving attention: revenue growth and raised full-year revenue guidance were offset by an earnings-per-share miss and weaker-than-expected EBITDA guidance, prompting a sharp selloff. Traders are divided between viewing the drop as an overreaction to the narrow miss and worrying about profitability, cash burn, and dilution risk.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock a Rising Oncology Opportunity With KRAS G12C Therapy Potential?

Is BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock a Rising Oncology Opportunity With KRAS G12C Therapy Potential...

What is HC Wainwright's Forecast for BBOT FY2026 Earnings?

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT - Free Report) - HC Wainwright cut their FY2026 earnings per share (EPS) estimates for shares of BridgeBio Oncology Therapeutics in a report issued...

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Hits New 52-Week Low - Here's What Happened

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Sets New 52-Week Low - Here's Why...

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Trading Up 4.9% - Here's What Happened

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Trading Up 4.9% - Still a Buy...

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Trading Down 5.8%  - Should You Sell?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Trading Down 5.8% - What's Next...

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Sees Large Volume Increase  - Still a Buy?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Sees Strong Trading Volume - Time to Buy...

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Stock Price Down 6.8% - What's Next?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Stock Price Down 6.8% - Time to Sell...

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Hits New 12-Month Low - Should You Sell?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Hits New 12-Month Low - Here's What Happened...

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Trading Down 1.3%  - Should You Sell?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Stock Price Down 1.3% - Should You Sell...

BridgeBio Oncology (BBOT) Spotlights Next-Gen RAS Pipeline, $425M Cash Runway Into 2028

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) used a presentation at Leerink Partners' Global Healthcare Conference to outline its strategy around next-generation RAS therapeutics, highlighting three...

Bridgebio Oncology Therapeutics, Inc. engages in developing bioavailable small molecule inhibitors. It focuses on advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. The company was founded on August 1, 2016 and is headquartered in South San Francisco, CA.

BridgeBio Oncology Therapeutics Inc.

Bullish Sentiment

Yes, by year-end

Yes, but not this year

No, he stays as CEO

He steps down on his own

Do you think Jensen Huang will be removed as Nvidia’s ($NVDA) CEO?

Stocktwits

Do you think Jensen Huang will be removed as Nvidia’s (

Stocktwits Polls

$BBOT Can someone explain this rationale :  
“The encouraging efficacy and safety profile with BBO-8520 plus pembrolizumab supports development in patients with KRASG12C-mutant NSCLC who have progressed on a prior G12C inhibitor, a growing population with significant unmet need,” said Yong (Ben) Ben, M.D., Chief Medical and Development Officer of BBOT. 
 
What is the though process on expecting a G12C inhibitor to work on patients who have progressed on G12C inhibitors? 
 
The way I see it is like thinking I bought 10mm wrench from Temu, did not fit quite right so I went to harbor Freight and bough another 10mm wrench and tried it and it didnt work and I wonder why

LabPsycho

$BBOT Latest analyst update, Oct 21, 2026: Morgan Stanley kept Overweight and cut its price target on BridgeBio Oncology Therapeutics to 13 USD from 18 USD. Third-party analyst opinion. 
 
More details in our $BBOT stock hub.  
Not investment advice.

Merlintrader Trading Pub

$BBOT 🏥 

BridgeBio Oncology Therapeutics, Inc. reported Q3 2026 clinical data showing BBO-8520 plus pembrolizumab achieved 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRAS G12C inhibitor-experienced NSCLC patients. 

Prioritized by relevance

Rayvio | Market News Filter

$BBOT Yikes...continues to take a beating. Could be tax loss selling and I expect many biotechs that have drifted down all year to get 'transient;y' oversold....before the next legs down next year.

$BBOT @Biotech_Pharma_Investor I would be very interested in your take on this (my post below)? 
I also wonder if they are satisfied with their BBO-8520 results as monotherapy going to try to sell the rights? Then again that doesnt make any sense to me if they are focusing on the combo.

Feed

News

Sentiment

Earnings

Fundamentals

Info

BBOT BridgeBio Oncology Therapeutics Inc.

Fundamentals

Latest BBOT News